Recent studies by Roudi et al. demonstrate that CD47 blockade not only suppresses tumor progression but its efficacy is enhanced when combined with agents capable of modifying the tumor epigenome, as these drugs can convert immunologically “cold” tumors to “hot,” promoting increased immune cell infiltration and responsiveness [131]. This evidence concerns the gene CD47 and neoplasm.